Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO-MARK: Ketamine Mechanisms in Treatment-Resistant Depression
NCT04977674Phase 1Completed
- Sponsor
- King's College London
- Start
- Sep 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in treatment-resistant depression (TRD) (2 arms), sponsored by King's College London. Primary endpoint: Change in Glutamate at 40 minutes. Started Sep 2021; status: completed.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04977674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977674.